Sildalis Tablets (Sildenafil 100 mg + Tadalafil 20 mg)

Most erectile dysfunction tablets contain a single active ingredient. Sildalis is different: each tablet combines 100 mg of sildenafil with 20 mg of tadalafil, placing sildenafil and tadalafil at their usual maximum erectile-dysfunction strengths in one dose. That single distinction changes how someone should assess its safety, dosing implications and differences from the single-ingredient options most people already know. If you are weighing this dual-ingredient tablet against a standard sildenafil or tadalafil product, that combination is the detail to understand before anything else.

What Sildalis actually is

We supply Sildalis as an oral tablet containing sildenafil and tadalafil together, at the fixed strength of 100 mg sildenafil plus 20 mg tadalafil. Both ingredients belong to the same drug class, phosphodiesterase type 5 (PDE5) inhibitors, but they are not interchangeable copies of one another. Sildenafil is the active ingredient behind well-known erectile dysfunction brands, while tadalafil is recognised for a longer duration of action. Sildalis brings both into a single tablet rather than offering them as two separate products, which is the core identity point to keep in mind whenever you compare it with either ingredient sold on its own.

We list Sildalis only in this combined 100 mg + 20 mg strength, with no separate sildenafil-only or tadalafil-only version under this product name. Anyone specifically wanting just one of the two ingredients should look at a single-ingredient alternative rather than expecting Sildalis to be adjustable to one component.

Who might consider Sildalis?

Sildalis may attract adult men with erectile dysfunction who are comparing a combined tablet with single-ingredient PDE5 inhibitors. However, using sildenafil and tadalafil together is not an established erectile-dysfunction regimen: the safety and efficacy of combining PDE5 inhibitors have not been adequately studied, and official product information recommends against taking them together because adverse effects may be additive.

• Anyone comparing Sildalis with sildenafil or tadalafil alone should recognise that one tablet contains the usual maximum erectile-dysfunction strength of each ingredient.
• Men who found a single-ingredient tablet insufficient should seek medical review rather than assuming that combining two PDE5 inhibitors is the appropriate next step.
• Anyone already using sildenafil, tadalafil, vardenafil, avanafil or another erectile-dysfunction medicine must account for both active ingredients already present in Sildalis.

Sildalis is not suitable for women, for anyone under 18, or for men who use nitrate medicines. It should also be avoided where sexual activity is inadvisable because of cardiovascular disease or where a clinician has advised against PDE5 inhibitors. Previous tolerance of sildenafil or tadalafil alone does not establish that taking both together will be safe.

How it works and what that means in practice

Sildenafil and tadalafil both work by blocking the PDE5 enzyme. During sexual stimulation, this helps cyclic GMP remain active in the smooth muscle of the penis, promoting relaxation of the corpus cavernosum and increased local blood flow. Neither ingredient creates sexual arousal by itself; sexual stimulation is still required for an erection. Because both act on the same pathway, combining them may also intensify class-related adverse effects rather than providing a predictable additional benefit.

The ingredients have different pharmacokinetic profiles. Sildenafil generally has a shorter period of action, while tadalafil remains in the body considerably longer. Sildalis contains both profiles in one tablet, but it should not be assumed that this reliably produces sildenafil's onset combined with tadalafil's longer window. The onset, duration, safety and efficacy of this fixed dual-PDE5 regimen have not been established in the way they have for licensed single-ingredient products.

How should Sildalis be taken?

There is no established recommended dosing regimen for this sildenafil-and-tadalafil combination. The separate product information for sildenafil and tadalafil advises against use with another PDE5 inhibitor, so dosing instructions for either ingredient alone should not be combined or automatically applied to Sildalis. A person considering it should have their medicines, cardiovascular health and suitability for sexual activity assessed by an appropriate healthcare professional.

• Do not take Sildalis with any additional sildenafil, tadalafil, vardenafil, avanafil or other PDE5 inhibitor.
• Do not repeat a dose on the assumption that it has failed to work; tadalafil remains in the body much longer than sildenafil, and extra dosing may increase adverse effects.
• A heavy, high-fat meal can delay sildenafil absorption, although tadalafil absorption is less affected by food.
• Keep alcohol intake modest, since excessive alcohol can increase dizziness, faintness and blood-pressure effects alongside PDE5 inhibitors.
• Store tablets at room temperature, between 20°C and 25°C, away from moisture, heat and direct light.

These are general safety and administration principles rather than a validated dosing schedule for Sildalis. Individual instructions should not be inferred solely from the usual dosing of sildenafil or tadalafil when each is used on its own.

Choosing a pack size

We offer Sildalis in one strength, 100 mg sildenafil + 20 mg tadalafil, in quantities of 10, 20, 30, 60, 90, 120, 180, 270 or 360 pills. Pack size changes the quantity supplied but not the strength or the safety considerations of the combined tablet. A smaller quantity limits the amount purchased initially, while larger quantities reduce how often an established customer needs to reorder. Quantity should not be used to determine dosing frequency or treated as a fixed course of treatment.

Expected outcomes and timing

When used separately for erectile dysfunction, sildenafil commonly begins working within about 30 to 60 minutes, while tadalafil may begin working from around 30 minutes and has a substantially longer potential period of responsiveness. Food, alcohol, health conditions and individual absorption can affect these timings. Those single-ingredient ranges do not establish a guaranteed onset or duration for Sildalis, and taking both ingredients together does not guarantee a stronger erection or a predictable extended effect. As with other PDE5 inhibitors, any erectile response still depends on sexual stimulation.

If an erectile-dysfunction medicine repeatedly does not produce the expected result, factors such as timing, food, stimulation, underlying cardiovascular or metabolic disease, psychological factors and interacting medicines may need review. Taking more tablets or adding another PDE5 inhibitor is not a safe way to troubleshoot a poor response.

What safety issues matter most?

Combining two PDE5 inhibitors at their usual maximum erectile-dysfunction strengths is the single most important safety point about Sildalis. Product information for sildenafil and tadalafil individually states that combining a PDE5 inhibitor with another PDE5 inhibitor has not been adequately studied and is not recommended, because of the risk of additive effects such as a marked drop in blood pressure, flushing, headache, dizziness or fainting.

• Sildalis should not be combined with any additional sildenafil, tadalafil, vardenafil or avanafil product, since Sildalis already delivers both sildenafil and tadalafil in one tablet.
• It is not intended for use during pregnancy or breastfeeding and is not indicated for women; these ingredient strengths are used for adult male erectile dysfunction.
• It is not intended for anyone under 18 years old.
• Common PDE5 inhibitor adverse effects include headache, flushing, nasal congestion and indigestion. Tadalafil can also cause back or muscle pain, while sildenafil can cause visual disturbance.
• Anyone with an unrelated allergy history is not automatically at risk, provided they are not specifically allergic to sildenafil, tadalafil or the tablet's excipients.

Sudden vision loss, sudden hearing loss, chest pain, fainting, a severe allergic reaction or an erection lasting more than four hours requires urgent medical attention rather than another dose. If chest pain occurs, the person should tell emergency professionals that sildenafil and tadalafil have been taken, because nitrates may interact dangerously with both ingredients. As either medicine can cause dizziness or visual disturbance, users should establish how they are affected before driving or operating machinery.

Interactions and practical precautions

PDE5 inhibitors interact with several medicine groups in ways that matter for anyone considering Sildalis, particularly because two PDE5 inhibitors are already present in a single tablet.

• Nitrates used for angina must not be combined with sildenafil or tadalafil, as the interaction can cause a dangerous fall in blood pressure. The same concern applies to nitric oxide donors such as amyl nitrite.
• Riociguat, a soluble guanylate cyclase stimulator, should not be combined with PDE5 inhibitors because symptomatic hypotension can occur.
• Alpha-blockers and other blood-pressure medicines can add to the blood-pressure-lowering effect of a PDE5 inhibitor, so suitability, timing and dose require medical review.
• Other PDE5 inhibitors, including sildenafil, tadalafil, vardenafil or avanafil taken separately, should not be added to Sildalis.
• Strong CYP3A4 inhibitors, including some azole antifungals, macrolide antibiotics and HIV protease inhibitors, can increase sildenafil or tadalafil exposure and the likelihood of adverse effects. CYP3A4 inducers may reduce exposure.
• Grapefruit or grapefruit juice can affect metabolism and may increase exposure to these medicines, so it is sensible to avoid the combination.
• People with diabetes, cardiovascular disease, severe kidney or liver impairment, low blood pressure, retinal disease, bleeding disorders, penile deformity or a predisposition to priapism need individual assessment.

A medicines review should include prescribed treatments, non-prescription products and recreational substances. This is particularly important when the exact name of an angina, blood-pressure, prostate, antifungal or antiviral medicine is uncertain.

Sildalis and Spedra: dual ingredients or one faster-acting option?

Spedra contains avanafil, a single PDE5 inhibitor that can have a relatively rapid onset, with some licensed doses taken approximately 15 to 30 minutes before sexual activity. It uses one active ingredient with established product-specific dosing rather than combining two PDE5 inhibitors. Sildalis takes a different approach by placing sildenafil and tadalafil together in one tablet, but that dual format is not an established way to secure both faster onset and longer duration, and combinations of PDE5 inhibitors are not recommended in official single-ingredient guidance.

Someone prioritising a single active ingredient and a licensed, product-specific dosing schedule may find an avanafil-based option easier to assess. The important distinction is therefore not simply speed versus duration: it is an established single-ingredient treatment compared with a dual-PDE5 tablet whose combined safety, efficacy and timing have not been adequately studied.

For readers who want to compare the individual ingredients found in Sildalis, our Viagra listing covers sildenafil citrate, and our Cialis listing covers tadalafil. Our Levitra listing offers vardenafil as another single-ingredient alternative. Readers comparing erectile-dysfunction treatments can also browse our Erectile Dysfunction range.

Is Sildalis available without a prescription in the UK?

We do not require a prescription to accept an order for Sildalis, so customers in the United Kingdom can order it without submitting one first. This describes our ordering policy and does not determine the prescription classification of sildenafil or tadalafil medicines generally. The sildenafil-and-tadalafil combination is not authorised for human medicinal use in the UK. Our ordering process does not change that regulatory position or the recommendation against combining PDE5 inhibitors, so the medical and safety considerations above remain important before an order is placed.

Ordering, delivery and receiving your order

We have operated our catalogue since 2017 and price Sildalis in pounds sterling, with quantities from 10 to 360 pills to suit different ordering preferences. Our support team is available 24/7 by email, online chat and phone, and our pharmacist can answer general medicine-related questions before or after an order. Once an order is placed, we pack and dispatch it promptly, with delivery estimates and tracking details provided at checkout so you know what to expect for your postcode before choosing a quantity.

When the parcel arrives, check that the product name, stated strength and quantity match the order. Keep the tablets in their supplied packaging and store them between 20°C and 25°C, protected from moisture, heat and direct light. Do not use tablets that appear damaged or whose packaging details do not match what was ordered; contact our support team instead.

Making the decision

Sildalis is defined by its dual-ingredient format: one tablet contains both sildenafil 100 mg and tadalafil 20 mg rather than one established PDE5 inhibitor alone. That may be the feature prompting comparison, but it is also the central safety concern. The combination has not been adequately studied, official single-ingredient guidance recommends against combining PDE5 inhibitors, and Sildalis must not be supplemented with another erectile-dysfunction tablet.

If the priority is a single well-characterised ingredient, a licensed product-specific dosing schedule or a more predictable onset and duration profile, a single-ingredient alternative such as sildenafil, tadalafil, vardenafil or avanafil is generally easier to assess. Anyone considering Sildalis should account for nitrates, riociguat, alpha-blockers, blood-pressure medicines, CYP3A4 interactions and relevant cardiovascular or other health conditions rather than treating the combined format as automatically more effective. We offer the listed pack quantities through our ordering process, with our support team and pharmacist available for general questions before a decision is made.